Summary
Charles Maussion is a machine learning and computational neuroscience entrepreneur with a decade of experience building AI-driven biomarkers and clinical research tools. As Co-founder of Karavela he’s pioneering foundation models of the brain trained on large-scale fMRI to accelerate diagnostics and clinical trials, following leadership of Biomarkers R&D at Owkin where he delivered translational projects and supervised multidisciplinary teams. Trained at École polytechnique and ENS Paris-Saclay (Master MVA), he blends rigorous statistical and computer vision expertise with hands-on model development proven in high-impact histology work. His background includes publishing a prognostic deep learning model (MesoNet) tied to Nature Medicine–level translational outcomes, reflecting a rare mix of academic rigor and product delivery. Based in Paris, he pairs startup operational experience with research-led innovation, often translating complex biomedical data into actionable clinical endpoints. Colleagues describe him as a connector between data science, clinical partners, and pharma, able to steer both code-level solutions and strategic product decisions.
10 years of coding experience
7 years of employment as a software developer
Master MVA (Mathématiques, Vision, Apprentissage), Master MVA (Mathématiques, Vision, Apprentissage) at ENS Paris-Saclay
Physique-Chimie, Physique-Chimie at Lycée Sainte-Geneviève
Data Science, Data Science at Ecole polytechnique
French, English, Chinese, Spanish